NEW YORK (GenomeWeb News) — Proteome Sciences said today it will use its ProteoShop services to analyze diagnostic antibodies related to prostate and colon cancer for Onconome.
 
Under the agreement, Proteome Sciences will use its 2-D gel Western blotting technology to characterize Onconome’s antibodies, and will use its 2-D gel electrophoresis and Tandem Mass Tags for further analysis.  
 
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.